Last news
Astronergy shines with its breakthroughs at Intersolar Europe 2025

Astronergy shines with its breakthroughs at Intersolar Europe 2025

No busbars, no limits: Astronergy showcases ZBB-powered solar breakthroughs in Munich MUNICH, May 12, 2025 /PRNewswire/ -- At Intersolar Europe 2025, Astronergy reaffirmed its leadership in solar innovation and international collaborations by...

Vipshop to Announce First Quarter 2025 Financial Results on May 20, 2025

Vipshop to Announce First Quarter 2025 Financial Results on May 20, 2025

GUANGZHOU, China, May 12, 2025 /PRNewswire/ -- Vipshop Holdings Limited (NYSE: VIPS), a leading online discount retailer for brands in China ("Vipshop" or the "Company"), today announced that it plans to release its first quarter 2025 financial...

Arya.ai Unveils MCP Applications to Transform Generic LLMs into Domain-Specific Experts

Arya.ai Unveils MCP Applications to Transform Generic LLMs into Domain-Specific Experts

MUMBAI, India and NEW YORK, May 12, 2025 /PRNewswire/ -- Arya.ai today announced the launch of its APEX MCP (Model Context Protocol) Client and Server applications. It's a breakthrough orchestration layer designed to turn general-purpose large...

HashKey Group Announces Launch of HashKey Global MENA with VASP License in UAE

HashKey Group Announces Launch of HashKey Global MENA with VASP License in UAE

HONG KONG, May 12, 2025 /PRNewswire/ -- HashKey Group ("HashKey"), a leading end-to-end digital asset financial services group in Asia Pacific, has secured a Virtual Asset Service Provider (VASP) license from Dubai Virtual Assets Regulatory...

Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first...

Zilliz Cloud Delivers Sub-10ms Latency and Cost Savings for AI-First Companies

Zilliz Cloud Delivers Sub-10ms Latency and Cost Savings for AI-First Companies

AI innovators report faster performance, greater reliability, and lower infrastructure costs by switching to Zilliz's fully managed vector database service. REDWOOD CITY, Calif., May 12, 2025 /PRNewswire/ -- Zilliz, creator of the world's most...

China takes another concrete action to maintain global strategic stability: Global Times editorial

China takes another concrete action to maintain global strategic stability: Global Times editorial

BEIJING, May 12, 2025 /PRNewswire/ -- Chinese President Xi Jinping returned to Beijing on Saturday evening after wrapping up a state visit to Russia and attending celebrations in Moscow marking the 80th anniversary of the victory of the Soviet...

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain

HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof. Mike Chan's longstanding vision of organ-specific, cell-specific...

menu
menu